Few people are aware that tuberculosis (TB) is still a global health threat. TB can be spread to anyone, mainly through cough. Each year 9 million people fall ill with TB and 1.5 million die from it, making it the second infectious killer worldwide after HIV/AIDS. Antimicrobial-resistant TB is an increasing problem Eastern Europe and large parts of Asia.
There is a major need for innovations in TB control. The World Health Organization’s new End TB strategy calls for global elimination of the disease by 2050, but recognizes that this cannot be achieved without an effective vaccine, improved diagnostics, better treatment and strengthened and massively scaled up delivery of services. This requires strong investments in research at each step of the R&D chain.
The Netherlands has a top position in research and innovation for TB. Several Dutch research institutes are among the world-leading groups in various aspects of TB research, owing to their expertise, research capacity, international networks and product innovation. Together they can make major contributions to the global TB research agenda.
KNCV Tuberculosis Foundation and the Netherlands Tuberculosis Research Platform (NTRP) joined forces, resulting in the White Paper ‘Dutch innovation for global TB elimination’, which articulates four areas of cutting-edge research, wherein Dutch groups can make the difference in future years.
15.30 Open Doors
16:00 Welcome and Opening
Myrthe Hilkens –journalist & former Member of Parliament
16:10 Innovation for TB elimination – the KNCV Perspective
Kitty van Weezenbeek – director KNCV Tuberculosis Foundation
16:20 Keynote: Translational research for TB elimination: priorities,
challenges and actions
Christian Lienhardt - senior research advisor, WHO Global
16:40 Presenting White Paper to Ministry of Education, Culture and
16:50 The Dutch TB Research Landscape
Martin Boeree – associate professor, Radboud University Medical
Center, and Chair Netherlands Tuberculosis Research Platform
17:00 White Paper Explained: Vaccines
Tom Ottenhoff – professor of Immunology at Leiden University Medical
17:10 White Paper Explained: Drug resistance
Frank Cobelens – scientific director of KNCV Tuberculosis Foundation
& professor of Epidemiology and Control of Poverty-related Infectious
Diseases at the Academic Medical Center, Amsterdam
17:20 Panel Discussion: working towards TB elimination by 2050 - is
this really possible with the Dutch TB research capacity?